This company has been marked as potentially delisted and may not be actively trading. (ANTX) (ANTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesTrendsBuy This Stock ANTX vs. SLN, NKTR, RAPT, ENTA, ATOS, LRMR, LYEL, NKTX, THTX, and IFRXShould you be buying (ANTX) stock or one of its competitors? The main competitors of (ANTX) include Silence Therapeutics (SLN), Nektar Therapeutics (NKTR), RAPT Therapeutics (RAPT), Enanta Pharmaceuticals (ENTA), Atossa Therapeutics (ATOS), Larimar Therapeutics (LRMR), Lyell Immunopharma (LYEL), Nkarta (NKTX), Theratechnologies (THTX), and InflaRx (IFRX). These companies are all part of the "pharmaceutical preparations" industry. (ANTX) vs. Silence Therapeutics Nektar Therapeutics RAPT Therapeutics Enanta Pharmaceuticals Atossa Therapeutics Larimar Therapeutics Lyell Immunopharma Nkarta Theratechnologies InflaRx Silence Therapeutics (NASDAQ:SLN) and (ANTX) (NYSE:ANTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, community ranking, media sentiment and dividends. Which has stronger valuation and earnings, SLN or ANTX? Silence Therapeutics has higher revenue and earnings than (ANTX). Silence Therapeutics is trading at a lower price-to-earnings ratio than (ANTX), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilence Therapeutics$27.70M5.47-$53.82M-$1.50-3.37(ANTX)N/AN/A-$64.73M-$2.04-0.58 Does the media favor SLN or ANTX? In the previous week, Silence Therapeutics had 1 more articles in the media than (ANTX). MarketBeat recorded 1 mentions for Silence Therapeutics and 0 mentions for (ANTX). Silence Therapeutics' average media sentiment score of 0.96 beat (ANTX)'s score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Silence Therapeutics Positive (ANTX) Neutral Do institutionals and insiders believe in SLN or ANTX? 98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 90.5% of (ANTX) shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 20.8% of (ANTX) shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts prefer SLN or ANTX? Silence Therapeutics currently has a consensus price target of $33.83, suggesting a potential upside of 568.64%. (ANTX) has a consensus price target of $1.50, suggesting a potential upside of 26.05%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Silence Therapeutics is more favorable than (ANTX).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71(ANTX) 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community favor SLN or ANTX? (ANTX) received 52 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 78.95% of users gave Silence Therapeutics an outperform vote while only 58.08% of users gave (ANTX) an outperform vote. CompanyUnderperformOutperformSilence TherapeuticsOutperform Votes4578.95% Underperform Votes1221.05% (ANTX)Outperform Votes9758.08% Underperform Votes7041.92% Which has more risk & volatility, SLN or ANTX? Silence Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, (ANTX) has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500. Is SLN or ANTX more profitable? (ANTX) has a net margin of 0.00% compared to Silence Therapeutics' net margin of -342.00%. (ANTX)'s return on equity of -57.62% beat Silence Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silence Therapeutics-342.00% -62.81% -33.89% (ANTX) N/A -57.62%-52.08% SummarySilence Therapeutics beats (ANTX) on 12 of the 17 factors compared between the two stocks. Get (ANTX) News Delivered to You Automatically Sign up to receive the latest news and ratings for ANTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANTX vs. The Competition Export to ExcelMetric(ANTX)Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$33.76M$6.48B$5.33B$19.29BDividend YieldN/A2.64%5.20%3.83%P/E Ratio-0.588.4026.7234.41Price / SalesN/A258.84395.5634.88Price / CashN/A65.8538.3217.52Price / Book0.286.416.764.69Net Income-$64.73M$143.73M$3.23B$1.02B (ANTX) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANTX(ANTX)N/A$1.19-2.5%$1.50+26.1%-40.8%$33.76MN/A-0.58N/ASLNSilence Therapeutics3.4578 of 5 stars$4.96+13.5%$33.83+582.1%-77.0%$130.79M$27.70M-3.16100NKTRNektar Therapeutics4.1416 of 5 stars$0.70+1.5%$4.50+547.5%-60.6%$129.34M$87.25M-0.83220Gap DownRAPTRAPT Therapeutics4.2572 of 5 stars$0.97+15.4%$4.00+313.3%-72.6%$128.04M$1.53M-0.3580News CoverageAnalyst UpgradeENTAEnanta Pharmaceuticals3.8362 of 5 stars$5.96+3.7%$17.25+189.4%-51.9%$127.41M$64.46M-1.20160ATOSAtossa Therapeutics2.036 of 5 stars$0.98+1.4%$7.13+624.4%-43.0%$127.05MN/A-4.478Gap DownLRMRLarimar Therapeutics1.9591 of 5 stars$1.95-1.8%$19.63+909.0%-75.0%$126.78MN/A-1.6930Positive NewsLYELLyell Immunopharma2.9311 of 5 stars$0.41-0.5%$1.00+142.1%-84.6%$122.57M$65,000.00-0.52270Positive NewsNKTXNkarta1.9577 of 5 stars$1.70-2.3%$14.67+762.7%-73.2%$120.63MN/A-0.90140Positive NewsGap UpTHTXTheratechnologiesN/A$2.61flatN/A+112.9%$120.01M$88.67M-26.10140IFRXInflaRx2.5581 of 5 stars$1.77+6.6%$8.50+380.2%+25.0%$118.83M$129,752.00-1.6460Gap Down Related Companies and Tools Related Companies SLN Competitors NKTR Competitors RAPT Competitors ENTA Competitors ATOS Competitors LRMR Competitors LYEL Competitors NKTX Competitors THTX Competitors IFRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANTX) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (ANTX) Please log in to your account or sign up in order to add this asset to your watchlist. Share (ANTX) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANTX Stock Free ANTX Stock Alerts